Elevated serum antibodies against insulin-like growth factor-binding protein-2 allow detecting early-stage cancers: evidences from glioma and colorectal carcinoma studies

Li, Y.; Jiang, Tao; Zhang, Jilin; Zhang, B.; Yang, Wenlei; You, Guoxiang; Xu, Ke; Wu, Jiangping; Luo, Cheng-Hua; Song, Shalei

doi:10.1093/annonc/mds007

Cited by 25 publications

(19 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Li et al (17) demonstrated that anti-IGFBP-2 antibody levels were higher in early cancers than advanced cancers in gliomas and colorectal cancer. When stratifying the analysis by American Joint Committee on Cancer stage for lung cancer, interestingly, a modest difference in anti-IGFBP-2 antibody levels was observed between early cancers and advanced cancers in lung cancer.…”

Section: Resultsmentioning

confidence: 99%

“…Serum IgG antibody against IGFBP-2 was assessed by indirect enzyme-linked immunosorbent assay (ELISA) as previously described (17). Briefly, Immulon 4HBX microtiter plates (Dynex), were coated overnight (at least for 24 h) with 50 μ l of highly purified, human recombinant IGFBP-2 protein (R&D Systems Inc., Minneapolis, MN) diluted in 50 ml carbonate buffer (Sigma-Aldrich Corp., St Louis, MO) to a concentration of 1.0 μ g/ml or carbonate buffer alone in alternating columns.…”

Section: Methodsmentioning

confidence: 99%

“…Although overexpressed IGFBP-2 is associated with increased tumor stages and grades (12), relapse, metastasis (14) and prognosis (16) in advanced cancers, it is less satisfactory in diagnosing early cancers. A recently published paper (17) first demonstrated that serum anti-IGFBP-2 antibody was significantly elevated in gliomas and colorectal carcinoma, suggesting that the detection of circulating anti-IGFBP-2 antibody may be a potential approach in diagnosing early cancers. In the current study, we aimed to evaluate whether serum IGFBP-2 and anti-IGFBP-2 antibody can be used as biomarkers in detection of lung cancer.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Autoantibodies against insulin-like growth factor-binding protein-2 as a serological biomarker in the diagnosis of lung cancer

Zhang

Xia

Han

et al. 2012

International Journal of Oncology

View full text Add to dashboard Cite

Insulin-like growth factor-binding protein-2 (IGFBP-2) is considered to be a human tumor antigen, and the tumor-specific immunity of IGFBP-2 has been reported in several types of cancer. The purpose of this study was to evaluate whether autoantibodies to IGFBP-2 can be used as diagnostic markers in lung cancer. The results demonstrated that serum anti-IGFBP-2 autoantibody levels were significantly elevated in lung cancer (mean, 1,633.318 ng/ml; median, 1,651.462 ng/ml; range, 342.732–4932.582 ng/ml) compared with benign lung disease (1,210.139, 1,035.900, 547.596–2,331.167 ng/ml) and normal controls (1,303.369, 1,194.800, 528.200–2140.500 ng/ml). The sensitivity and specificity of anti-IGFBP-2 autoantibodies in diagnosing lung cancer was 73.2 and 60.6%, respectively. When serum IGFBP-2 and anti-IGFBP-2 autoantibody were used together in the diagnosis of lung cancer, it can increase the discriminative power for lung cancer with a sensitivity of 85.7% and a specificity of 57.5%. In conclusion, this study demonstrates that circulating anti-IGFBP-2 autoantibodies can be used as a potential biomarker in diagnosing lung cancer.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Autoantibodies against insulin-like growth factor-binding protein-2 as a serological biomarker in the diagnosis of lung cancer

Zhang

Xia

Han

et al. 2012

International Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…In addition, over the past 15 years, results of several studies reporting increased expression of IGFBP-2 have correlated it with poor clinical GBM patient outcomes 56–59. Moreover, recent studies have reported that plasma IGFBP-2 levels could predict the clinical outcomes of GBM patients 25,60,61. IGFBP-2 expression has been associated with oncogenic effects via several mechanisms.…”

Section: Discussionmentioning

confidence: 99%

<em>FBLN4</em> as candidate gene associated with long-term and short-term survival with primary glioblastoma

Li¹,

Li²,

Zhang³

et al. 2017

OTT

View full text Add to dashboard Cite

BackgroundGlioblastoma multiforme (GBM) is the most common malignant and lethal type of primary central nervous system tumor in humans. In spite of its high lethality, a small percentage of patients have a relatively good prognosis, with median survival times of 36 months or longer. The identification of clinical subsets of GBM associated with distinct molecular genetic profiles has made it possible to design therapies tailored to treat individual patients.MethodsWe compared microarray data sets from long-term survivors (LTSs) and short-term survivors (STSs) to screen for prognostic biomarkers in GBM patients using the WebArrayDB platform. We focused on FBLN4, IGFBP-2, and CHI3L1, all members of a group of 10 of the most promising, differentially regulated gene candidates. Using formalin-fixed paraffin-embedded GBM samples, we corroborated the relationship between these genes and patient outcomes using methylation-specific polymerase chain reaction (PCR) for MGMT methylation status and quantitative reverse transcription PCR for expression of these genes.ResultsExpression levels of the mRNAs of these 3 genes were higher in the GBM samples than in normal brain samples and these 3 genes were significantly upregulated in STSs compared to the levels in LTS samples (P<0.01). Furthermore, Kaplan–Meier analysis showed that the expression patterns of FBLN4 and IGFBP-2 serve as independent prognostic indicators for overall survival (P<0.01 and P<0.05, respectively).ConclusionTo our knowledge, this is the first report describing FBLN4 as a prognostic factor for GBM patient survival, demonstrating that increased GBM survival time correlates with decreased FBLN4 expression. Understanding FBLN4 expression patterns could aid in the creation of powerful tools to predict clinical prognoses of GBM patients.

show abstract

“…Coincidently, we have found that the high expression of FCRG2B ( CD32B ), the inhibitor of antigen presentation and antibody production by B cells, occurs in the high risk group, which was opposite with the preferential occurrence of IDH1 mutation in the low risk group. Our previous study showed that the plasma of patients of low grade tumors contained a higher level of IgG autoantibodies against tumor-associated antigen IGFBP2 than that of high grade tumor patients [53]. …”

Section: Discussionmentioning

confidence: 99%

Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference

Zhang

Wang

et al. 2016

Oncotarget

View full text Add to dashboard Cite

High grade gliomas contribute to most brain tumor mortality. A few studies reported that the immune system affected glioma development, and immune biomarkers helped understand the disease and formulate effective immunotherapy for patients. Currently, no B lymphocyte-based prognostic signature was reported in gliomas. By applying 78 B cell lineage-specific genes, we conducted a whole-genome gene expression analysis in 782 high grade gliomas derived from three independent datasets by Cox regression analysis and risk score method for signature identification, and then used Gene Ontology, Gene Set Enrichment Analysis, and other statistical methods for functional annotations of the signature-defined differences. We developed a five B cell-associated gene signature for prognosis of high grade glioma patients, which is independent of clinicopathological and genetic features. The signature identified high risk patients suitable for chemoradiotherapy, whereas low risk patients should rule out chemotherapy with radiotherapy only. We found that tumors of TCGA Mesenchymal subtype and wild type IDH1 were preferentially stratified to the high risk group, which bore strong immunosuppressive microenvironment, while tumors of TCGA Proneural subtype and mutated IDH1 were significantly accumulated to the low risk group, which exhibited less immunosuppressive state. The five B cell-associated gene signature predicts poor survival of high risk patients bearing strong immunosuppression and helps select optimal therapeutic regimens for glioma patients.

show abstract

Elevated serum antibodies against insulin-like growth factor-binding protein-2 allow detecting early-stage cancers: evidences from glioma and colorectal carcinoma studies

Cited by 25 publications

References 27 publications

Autoantibodies against insulin-like growth factor-binding protein-2 as a serological biomarker in the diagnosis of lung cancer

Autoantibodies against insulin-like growth factor-binding protein-2 as a serological biomarker in the diagnosis of lung cancer

<em>FBLN4</em> as candidate gene associated with long-term and short-term survival with primary glioblastoma

Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference

Contact Info

Product

Resources

About